Eight years ago, Germany required comparisons between all newly introduced drugs and existing options, such as the standard of care, to gauge their benefit as a basis for price negotiations. But a new analysis finds that between 2011 and 2017, only a minority of new medicines offered a meaningful benefit, leading government analysts to ask: “Where did we go wrong?”

The law emerged in the face of rising drug prices, a problem that has only accelerated in the intervening years. This prompted officials at the government agency that assesses clinical evidence — the Institute for Quality and Efficiency in Health Care, or IQWiG — to explore whether the approach was actually leading to greater value.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy